Suresh Pichandi et al. / Int J Cur Sci Res. 2011; 1(2): 47 - 56.
56
[34] Spearman ME, Summers K, Moore V, Jacqmin R, Smith G, Groshen S. Cost-
effectiveness of initial therapy with 3-hydroxy-3-methylglutaryl coenzyme
A reductase inhibitors to treat hypercholesterolemia in a primary care
setting of a managed-care organization. Clin Ther. 1997;19:582-539.
[35] Cucherat M, Boissel JP. A mathematical model for the determination of the
optimum value of the treatment threshold for a continuous risk factor. Eur J
Epidemiol. 1998 Jan;14(1):23-29.
[36] Morris S. A comparison of economic modelling and clinical trials in the
economic evaluation of cholesterol-modifying pharmacotherapy. Health
Econ. 1997 ;6:589-601.
[37] Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering
drugs: mechanisms and clinical relevance.2006;9:565-581.
[38]Lim SS, Vos T, Peeters A, Liew D, McNeil JJ. Cost-effectiveness of prescribing
statins according to pharmaceutical benefits scheme criteria. Med J Aust.
2001 ;175:459-464.
[39] Kendrick J,Shlipak MG, Targher G, Cook T, Lindenfeld J, Chonchol M. Effect of
lovastatin on primary prevention of cardiovascular events in mild CKD and
kidney function loss: a post hoc analysis of the Air Force/Texas Coronary
Atherosclerosis Prevention Study.
[40]Dotani MI, Elnicki DM, Jain AC,Gibson CM. Effect of preoperative statin
therapy and cardiac outcomes after coronary artery bypass grafting. Am J
Cardiol .2000; 86:1128-1130.
[41]Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM,
Davignon J, Erbel R.Effect of very high-intensity statin therapy on regression
of coronary atherosclerosis: the ASTEROID trial.JAMA.2006;13:1556-65.
© Copyright 2011. CurrentSciDirect Publications. IJCSR - All rights reserved.